latest news releases from the newsroom
Ceragenix and MAST BioSurgery Enter Into Joint Development Agreement for New Antimicrobial Surgical Products
DENVER, Apr 29, 2009 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into a Joint Development Agreement ("JDA") with MAST BioSurgery Inc. ("MAST") for the development of one or more new surgical products incorporating Ceragenix's CeraShield(TM) antimicrobial technology. Under the terms of the JDA, MAST will have exclusive rights to develop specified products and negotiate commercialization terms for such products for a period of six months. This is the first joint development and exclusive option to license entered into by Ceragenix for a medical device application of its CeraShield(TM) antimicrobial technology.